183896-00-6

Basic information

• Product Name: N-(13-amino-4,7,10-trioxatridecanyl)-D-biotinamide
• Synonyms: N-(13-amino-4,7,10-trioxatridecanyl)-D-biotinamide
• CAS NO: 183896-00-6
• Molecular Weight: 446.612
• Mol File: 183896-00-6.mol

Chemical Properties

• CAS DataBase Reference: N-(13-amino-4,7,10-trioxatridecanyl)-D-biotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(13-amino-4,7,10-trioxatridecanyl)-D-biotinamide(183896-00-6)
• EPA Substance Registry System: N-(13-amino-4,7,10-trioxatridecanyl)-D-biotinamide(183896-00-6)

Safety Data

• Hazardous Substances Data: 183896-00-6(Hazardous Substances Data)

Upstream product

• 4246-51-9 4,7,10-trioxa-1,13-diaminotridecane 
• 35013-72-0 biotin N-Hydroxysuccinimide ester 
• 142685-25-4 2,3,5,6-tetrafluorophenyl 2,2,2-trifluoroacetate 
• 58-85-5 biotin 
• 173341-32-7 biotin 2,3,5,6-tetrafluorophenyl ester 
• 194920-63-3 tert-butyl (15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)carbamate 
• 194920-62-2 tert-butyl N-(3-{2-[2-(3-aminopropoxy)ethoxy]ethoxy}propyl)carbamate 
• 452309-60-3 C₁₂H₂₃F₃N₂O₄ 
• 475114-55-7 C₂₂H₃₇F₃N₄O₆S 
• 927888-44-6 3-(2-(2-(3-(trityl-amino)-propoxy)-ethoxy)-ethoxy)-propylamine 
• 120550-35-8 biotin pentafluorophenyl ester 

Downstream Products

• 1047997-48-7 C₃₆H₅₂F₂N₄O₆S 
• 1219440-79-5 (E)-4-((5-(2-azidoethyl)-2-hydroxyphenyl)diazenyl)-N-(15-oxo-19-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)benzamide 
• 1338951-00-0 C₃₅H₄₉N₉O₈S 
• 1383627-51-7 C₄₂H₅₃N₇O₅S 
• 1407593-35-4 C₃₄H₄₅N₉O₆S 
• 1431957-52-6 N-(15-oxo-19-((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)-4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzamide 
• 1620484-40-3 C₃₈H₅₄N₄O₁₂S 
• 473912-42-4 ((R)-2-Hydroxy-2-{3-[2-(2-{3-[5-((3aR,6S,6aS)-2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-propoxy}-ethoxy)-ethoxy]-propylcarbamoyl}-ethyl)-carbamic acid 2-[3-nitro-5-(3-trifluoromethyl-3H-diazirin-3-yl)-phenoxy]-ethyl ester 

Relevant articles and documents

Changshanone derivatives and their pharmaceutical compositions and uses

The present application relates to a changshanone derivative and a pharmaceutical composition and use thereof, the changshanone derivative is shown in formula I, wherein m is 1 to 4, n is 1 to 10, A is H or a detection marker, such as a biotin marker. The present application further relates to a pharmaceutical composition comprising a derivative of changshanone of formula I and its application in the treatment of cancer. Equation I.

Synthesis of Na2S2O4 mediated cleavable affinity tag for labeling of O-GlcNAc modified proteins via azide-alkyne cycloaddition

A facile and convergent procedure for the synthesis of azobenzene-based probe was reported, which could selectively release interested proteins conducted with sodium dithionite. Besides, the cleavage efficiency is closely associated with the structural features, in which an ortho-hydroxyl substituent is necessary for reactivity. In addition, the azobenzene tag applied in the Ac4GlcNAz-labled proteins demonstrated high efficiency and selectivity in comparison with Biotin-PEG4-Alkyne, which provides a useful platform for enrichment of any desired bioorthogonal proteomics.

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)

Protein-protein interactions (PPIs) have emerged as significant targets for therapeutic development, owing to their critical nature in diverse biological processes. An ideal PPI-based target is the protein myeloid cell leukemia 1 (MCL1), a critical prosurvival factor in cancers such as multiple myeloma where MCL1 levels directly correlate to disease progression. Current strategies for halting the antiapoptotic properties of MCL1 revolve around inhibiting its sequestration of proapoptotic factors. Existing inhibitors disrupt endogenous regulatory proteins; however, this strategy actually leads to an increase of MCL1 protein levels. Here, we show the development of hetero-bifunctional small molecules capable of selectively targeting MCL1 using a proteolysis targeting chimera (PROTAC) methodology leading to successful degradation. We have confirmed the involvement of the E3 ligase CUL4A-DDB1 cereblon ubiquitination pathway, making these PROTACs a first step toward a new class of antiapoptotic B-cell lymphoma 2 family protein degraders.

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

The present disclosure is directed to compounds of formula I and methods of their use and preparation, as well as compositions comprising compounds of formula I.

POLYCYCLIC EPOXIDES AND COMPOSITIONS THEREOF WITH ANTI-CANCER ACTIVITIES

The present technology provides polycyclic epoxides of Formula I, compositions comprising such expoxides and methods of using such epoxides. In particular, these compounds are useful for inhibiting cancer cell proliferation and tumor angiogenesis or treating ovarian, breast, prostate, liver, pancreatic, and colon cancers, as well as leukemia.

TRIFUNCTIONAL CROSSLINKING REAGENTS

The present invention relates to trifunctional crosslinking reagents as defined in claim 1, where HRN is a hydrazine-protecting group selected from hydrazones (R'R"C=NNH2), said hydrazone being aldehyde or ketone hydrazone, said substituents R', R" being selected from hydrogen, substituted (C1-C6)alkyl, substituted aryl and substituted heteroaryl. The invention further provides trifunctional crosslinking reagents suitable for the detection, isolation and purification of captured glycopeptides, their methods of production, as well as their use in methods for detecting, identifying and characterizing interactions between ligands and their corresponding glycoprotein target receptors on living cells and in biological fluids.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

HIGH AFFINITY DIGOXIGENIN BINDING PROTEINS

Isolated polypeptides with steroid binding activity and methods for their use as therapeutics and detection agents are disclosed herein.

New affinity-based probes for capturing flavonoid-binding proteins

Flavonoid-bearing probes have been designed and synthesized to explore their ability to selectively capture target proteins or biosynthetic enzymes under oxidative activation. A proof-of-concept study using biotinylated (epi)catechin-bearing affinity-based probes herein demonstrates the ability of these probes to capture the LDOX flavonoid enzyme using sodium periodate as the oxidant.

A quartz crystal microbalance method to study the terminal functionalization of glycosaminoglycans

We demonstrate the quartz crystal microbalance as a novel method to quantify the reaction yields and stability of the terminal conjugation of chemically complex molecules. Oxime ligation is identified as a facile, broadly applicable method for the reducing-end conjugation of glycosaminoglycans that overcomes the limited stability and yield of popular hydrazone ligation.